All In Biotech

Drug Trial Radar · NCT07538804

A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS02 in Participants With EGFR Mutation-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

294

Planned (sponsor's estimate)

Start

Jul 10, 2026

Primary completion

Jun 30, 2029

Study completion Oct 30, 2029

Sponsor

Sponsor type
Industry
First posted
Apr 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human (FIH) Phase I/II, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS02 as monotherapy.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • ANS02Drug

    4 dose levels would be explored during the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs)Time frame: From the time of first dose to 28 days post last dose of ANS02
  2. Incidence of Serious Adverse Events (SAEs)Time frame: From time of first dose to 28 days post last dose of ANS02
  3. Incidence of dose-limiting toxicities (DLT) as defined in the protocolTime frame: From time of first dose of ANS02 to end of DLT period (approximately 28 days)
  4. Incidence of baseline laboratory finding, ECG and vital signs changesTime frame: From time of first dose to 28 days post last dose of ANS02

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    Fairfax, Virginia · Recruiting

  • Research Site

    Guangzhou, Guangdong, China · Not yet recruiting

  • Research Site

    Harbin, Heilongjiang, China · Recruiting

  • Research Site

    Zhengzhou, Henan, China · Not yet recruiting

  • Study Site

    Chengdu, Sichuan, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.